NEW YORK, September 14, 2010 /PRNewswire/ -- Elsevier today announces that it has significantly increased its service offering to pharmaceutical RD professionals with the launch of a new Pharmacokinetics Module of PharmaPendium(TM), the online resource for authoritative drug development data. The Pharmacokinetics Module allows pharmacokineticists (and related professionals in regulatory affairs, preclinical, safety pharmacology, etc.) to access multiple exposure parameter measurements under various experimental conditions for over 2,100 drugs, enabling the retrieval and analysis of over 1,000,000 pharmacokinetic observations.
The new Pharmacokinetics Module is not only a faster and more efficient way to search pharmacokinetics data, it is the only place to find this level of comparative exposure information, great for modeling and comparing therapeutic windows earlier in the development process, said Philip MacLaughlin, Senior Product Manager at Elsevier. This is a level of information that stands alone as a resource for Pharmacokinetics data, as it can save months of work.
With the Pharmacokinetics Module, RD professionals can model therapeutic windows faster and more accurately than previously possible and discover which preclinical experimental data is predictive of human response, which is not, and why. Users will have the ability to filter comparative data sets for decision support according to a wide variety of fields and special designations, including drug name, species, disease state, food effects, concomitant drugs, route, and exposure parameter.
The PharmaPendium(TM) module is available exclusively to existing PharmaPendium(TM) customers. Purchase options include annual subscription or data purchase (with annual maintenance fee).
About PharmaPendium(TM)
PharmaPendium(TM) (http://www.info.pharmapendium.com/), allows the user to make informed drug development decisions. It is a unique online resource that provides access via a single point to searchable and trusted drug information. It covers close to 4,000 approved drugs, with integrated preclinical, clinical and post-market safety data.
PharmaPendium(TM) is designed to meet the needs of preclinical safety assessment teams, toxicologists, pharmacokineticists, safety pharmacologists, regulatory affairs staff, pharmacoepidemiologists, clinical researchers, drug discovery informatics and information specialists. It enables text-search of FDA Approval Packages and European Medicines Agency (EMEA) European Public Assessment Reports (EPAR) Approval Documents as well as other data sources. Adverse events and toxicity data are carefully extracted from preclinical and clinical studies from all of these sources. Elsevier offers a broad spectrum of solutions to make processes in drug discovery, preclinical and clinical drug development more efficient, e.g. Reaxys (http://www.info.reaxys.com), Embase (http://www.info.embase.com) and PharmaPendium(TM) ( http://www.info.pharmapendium.com). PharmaPendium(TM) is owned and protected by Elsevier Properties SA and used under license.
About Elsevier
Elsevier is a world-leading publisher of scientific, technical and medical information products and services. The company works in partnership with the global science and health communities to publish more than 2,000 journals, including The Lancet (http://www.thelancet.com) and Cell (http://www.cell.com), and close to 20,000 book titles, including major reference works from Mosby and Saunders. Elsevier's online solutions include ScienceDirect http://www.sciencedirect.com), Scopus (http://www.scopus.com), Reaxys (http://www.reaxys.com), MD Consult (http://www.mdconsult.com) and Nursing Consult (http://www.nursingconsult.com), which enhance the productivity of science and health professionals, and the SciVal suite (http://www.scival.com) and MEDai's Pinpoint Review (http://www.medai.com), which help research and health care institutions deliver better outcomes more cost-effectively.
A global business headquartered in Amsterdam, Elsevier ( http://www.elsevier.com) employs 7,000 people worldwide. The company is part of Reed Elsevier Group PLC (http://www.reedelsevier.com), a world-leading publisher and information provider, which is jointly owned by Reed Elsevier PLC and Reed Elsevier NV. The ticker symbols are REN (Euronext Amsterdam), REL (London Stock Exchange), RUK and ENL (New York Stock Exchange).
About Elsevier Properties SA
Elsevier Properties SA is a center of excellence within Reed Elsevier for the management of intellectual property. Elsevier Properties SA owns the PharmaPendium(TM), Beilstein and Reaxys databases. Trademarks including Reaxys(R), PharmaPendium(TM) and The Lancet(R) are owned and protected by Elsevier Properties SA and used under license. For additional information see http://www.reedelsevier.com.
Media Contact Tom Reller VP, Global Corporate Relations +1-215-239-3508 T.Reller@elsevier.com
SOURCE: Elsevier and Elsevier Properties SA
CONTACT: Media Contact: Tom Reller, VP, Global Corporate Relations,+1-215-239-3508, T.Reller@elsevier.com
Comments